ARTICLE | Product Development
Target wide, test narrow in lupus
How the lupus field can springboard from its seven late-stage misses in 2018
January 26, 2019 3:03 AM UTC
While last year’s spate of clinical misses in lupus leave the field still in search of optimal targets, the 2019 outlook isn’t all doom. Companies with shots on goal are using sharper endpoints and aiming for targets with broader effects on disease biology.
2018 failed to add positively to the record of the last 50 years, which has seen only one targeted therapy approved to treat lupus...